A European active pharmaceutical ingredient (API) manufacturer required full containment of trace pharmaceutical compounds in its wastewater, combined with 80% water reuse to meet its corporate water neutrality commitment.
A Central European facility manufacturing APIs for cardiovascular and oncology drugs generated 1,200 m³/day of complex mixed wastewater containing: (1) API-bearing process effluent at concentrations up to 50 mg/L API; (2) CIP and rinse water with high BOD and surfactants; (3) solvent-bearing condensates from distillation. Key constraints:
Reynolds & Bauhm designed a multi-stage treatment train combining solvent stripping, biological treatment, AOP, and membrane polishing:
| Stage | Equipment / Process | Key Parameter |
|---|---|---|
| 1 | Steam stripping column | Removes solvents; condensate recovery to production |
| 2 | 500 m³ equalisation tank | Dampens batch peaks to ±20% of average COD |
| 3 | MBR (hollow-fibre UF membranes, 0.04 µm) | BOD <10 mg/L; TSS <1 mg/L; partial API degradation |
| 4 | UV/H&sub2;O&sub2; AOP reactor | UV 1,500 mJ/cm²; H&sub2;O&sub2; 30 mg/L; API destruction to <0.05 µg/L |
| 5 | Catalase H&sub2;O&sub2; quench | Residual H&sub2;O&sub2; <0.5 mg/L |
| 6 | RO polishing (85% recovery) | Permeate conductivity <50 µS/cm; reused as cooling tower make-up |
| 7 | GAC polishing (permeate stream) | Trace organics insurance barrier; EBCT 10 min |
All monitored APIs below 0.05 µg/L in final discharge, comfortably below 0.1 µg/L permit limit. Facility achieved EMA environmental risk assessment approval for the new discharge regime.
82% of treated water returned to cooling tower make-up and utility use. Annual water procurement reduced by 360,000 m³, valued at approximately at local tariff.
Facility achieved water neutrality certification for its production site. Scope 3 water intensity KPI reduced by 81%, supporting group ESG reporting.
Complete batch records, validation documentation, and environmental permit reporting aligned with FDA, EMA, and local regulatory requirements.
Wastewater treatment and water reuse for API and formulation facilities.
PharmaceuticalUV/H&sub2;O&sub2;, Fenton, and ozone AOP for refractory pharmaceutical compounds.
AOP SystemsOur engineers are available to review your site conditions and recommend the most appropriate treatment solution.
Pharmaceutical wastewater combines high and variable organic loads with active pharmaceutical ingredients, solvents and constituents that are toxic or inhibitory to conventional biology — and it is produced under a regulatory spotlight that demands documented, validated performance. Treating it well means matching the train to the chemistry: equalisation to absorb batch variability, advanced oxidation or adsorption to address APIs and refractory organics, and robust biological treatment protected from inhibition. Because the sector requires evidence, we build in the monitoring and documentation that prove removal. The result is a treatment scheme that meets tight discharge limits reliably while standing up to the validation and audit expectations placed on pharmaceutical manufacturing.
Our expertise spans multiple industries with sector-specific water treatment solutions.